These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8499586)

  • 1. Dual effect of valproic acid on the pharmacokinetics of phenytoin.
    Lai ML; Huang JD
    Biopharm Drug Dispos; 1993 May; 14(4):365-70. PubMed ID: 8499586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unbound plasma phenytoin concentrations measured using enzyme immunoassay technique on the cobas MIRA analyser--in vivo effect of valproic acid.
    Sallustio BC; Morris RG
    Ther Drug Monit; 1992 Feb; 14(1):9-13. PubMed ID: 1546396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects.
    Perucca E; Hebdige S; Frigo GM; Gatti G; Lecchini S; Crema A
    Clin Pharmacol Ther; 1980 Dec; 28(6):779-89. PubMed ID: 6777108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased plasma protein binding of phenytoin in patients on valproic acid.
    Dahlqvist R; Borgå O; Rane A; Walsh Z; Sjöqvist F
    Br J Clin Pharmacol; 1979 Dec; 8(6):547-52. PubMed ID: 391256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin.
    Lai ML; Lin TS; Huang JD
    Eur J Clin Pharmacol; 1992; 43(2):201-3. PubMed ID: 1425879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers.
    Blum RA; Schentag JJ; Gardner MJ; Wilner KD
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):35S-38S. PubMed ID: 7547092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-regulation of phenytoin and tolbutamide metabolism in humans.
    Tassaneeyakul W; Veronese ME; Birkett DJ; Doecke CJ; McManus ME; Sansom LN; Miners JO
    Br J Clin Pharmacol; 1992 Dec; 34(6):494-8. PubMed ID: 1493081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.
    Milne RW; Coulthard K; Nation RL; Penna AC; Roberts G; Sansom LN
    Br J Clin Pharmacol; 1988 Sep; 26(3):330-3. PubMed ID: 3179171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid in epilepsy: clinical and pharmacological effects.
    Mattson RH; Cramer JA; Williamson PD; Novelly RA
    Ann Neurol; 1978 Jan; 3(1):20-5. PubMed ID: 350128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma protein binding interaction between phenytoin and valproic acid in vitro.
    Monks A; Boobis S; Wadsworth J; Richens A
    Br J Clin Pharmacol; 1978 Dec; 6(6):487-92. PubMed ID: 365209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid.
    May TW; Rambeck B; Nothbaum N
    Eur Neurol; 1991; 31(1):57-60. PubMed ID: 2015840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children.
    ter Heine R; van Maarseveen EM; van der Westerlaken MM; Braun KP; Koudijs SM; Berg MJ; Malingré MM
    J Child Neurol; 2014 Jun; 29(6):803-10. PubMed ID: 23670246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of valproic acid with phenytoin.
    Bruni J; Gallo JM; Lee CS; Perchalski RJ; Wilder BJ
    Neurology; 1980 Nov; 30(11):1233-6. PubMed ID: 6775245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of phenytoin clearance by valproic acid in normal subjects.
    Frigo GM; Lecchini S; Gatti G; Perucca E; Crema A
    Br J Clin Pharmacol; 1979 Dec; 8(6):553-6. PubMed ID: 391257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous valproate: effects on plasma and saliva phenytoin levels.
    Pisani FD; Di Perri RG
    Neurology; 1981 Apr; 31(4):467-70. PubMed ID: 6783979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug interactions with phenytoin (Part I).
    Nation RL; Evans AM; Milne RW
    Clin Pharmacokinet; 1990 Jan; 18(1):37-60. PubMed ID: 2178849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers.
    Nolan PE; Marcus FI; Hoyer GL; Bliss M; Gear K
    Clin Pharmacol Ther; 1989 Jul; 46(1):43-50. PubMed ID: 2743707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication.
    May T; Rambeck B
    Ther Drug Monit; 1990 Mar; 12(2):124-8. PubMed ID: 2107607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of phenytoin and valproic acid in critically ill patients at Windhoek Central Hospital, Namibia.
    Singu BS; Morrison H; Irengeya L; Verbeeck RK
    Afr J Lab Med; 2022; 11(1):1628. PubMed ID: 35937763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.